Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group

Br J Cancer. 2003 Mar 10;88(5):645-7. doi: 10.1038/sj.bjc.6600823.

Abstract

The management of aggressive fibromatosis (AF) is problematic, and few options are available to patients unsuitable for surgery and resistant to external-beam radiation therapy (EBRT). We report on two patients with fast-growing recurrences of AF resistant to EBRT who obtained protracted clinical benefits with (90)Y-DOTATOC. (90)Y-DOTATOC should be further investigated in this setting.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • Fibromatosis, Aggressive / radiotherapy*
  • Humans
  • Male
  • Octreotide / analogs & derivatives*
  • Octreotide / therapeutic use*
  • Radiopharmaceuticals / therapeutic use*
  • Radiotherapy, Adjuvant / methods*
  • Receptors, Peptide / therapeutic use*
  • Recurrence
  • Retrospective Studies

Substances

  • Radiopharmaceuticals
  • Receptors, Peptide
  • Octreotide
  • Edotreotide